Viridian Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell VRDN and other ETFs, options, and stocks.

About VRDN

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis.

CEO

Stephen Frank Mahoney

CEOStephen Frank Mahoney

Employees

143

Employees143

Headquarters

Waltham, Massachusetts

HeadquartersWaltham, Massachusetts

Founded

2006

Founded2006

Employees

143

Employees143

VRDN Key Statistics

Market cap

3.10B

Market cap3.10B

Price-Earnings ratio

-9.19

Price-Earnings ratio-9.19

Dividend yield

—

Dividend yield—

Average volume

1.79M

Average volume1.79M

High today

$33.34

High today$33.34

Low today

$30.91

Low today$30.91

Open price

$31.30

Open price$31.30

Volume

1.26M

Volume1.26M

52 Week high

$33.34

52 Week high$33.34

52 Week low

$9.90

52 Week low$9.90

Stock Snapshot

As of today, Viridian Therapeutics(VRDN) shares are valued at $32.46. The company's market cap stands at 3.1B, with a P/E ratio of -9.19.

On 2025-12-04, Viridian Therapeutics(VRDN) stock traded between a low of $30.91 and a high of $33.34. Shares are currently priced at $32.46, which is +5.0% above the low and -2.6% below the high.

The Viridian Therapeutics(VRDN)'s current trading volume is 1.26M, compared to an average daily volume of 1.79M.

In the last year, Viridian Therapeutics(VRDN) shares hit a 52-week high of $33.34 and a 52-week low of $9.90.

Analyst ratings

94%

of 18 ratings

Buy

94.4%

Hold

5.6%

Sell

People also own

Based on the portfolios of people who own VRDN. This list is generated using Robinhood data, and it’s not a recommendation.